Microcap Ledger Volitionrx Ltd $VNRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Henderson, NV
- Fiscal year end
- December 31
- Shares outstanding
- 13,649,384 [10-Q 2026-08-13]
What the company doesAI summary of filing
VolitionRx Limited is a pre-revenue epigenetics company developing blood-based diagnostic tests to detect and monitor cancers and diseases associated with NETosis, such as sepsis. The company uses patented technologies based on nucleosome quantification and circulating tumor DNA capture to identify disease biomarkers in blood samples. VolitionRx generates revenue through licensing agreements with diagnostic companies and veterinary distributors, milestone payments, royalties, and kit sales; it recorded its first revenue from a regulated, clinically approved product in the first quarter of 2025 from sales of its CE-marked Nu.Q® NETs test in Europe. The company is at the clinical and early commercialization stage, with one CE-marked human product in limited commercial use, one veterinary product commercially available in multiple countries, and several additional products in development or seeking regulatory approval. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.38M | −$13.99M | −$10.44M | $2.80M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $1.73M | −$23.36M | −$19.68M | $1.12M | [10-K 2026-03-31] |
| FY ended Dec 2024 | $1.23M | −$26.97M | −$25.89M | $3.26M | [10-K 2026-03-31] |
- Quarterly cash burn
- −$5.22M
- Cash runway Estimate
- ~1.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-20 | 96,543,744 | [10-K 2025-03-31] |
| 2025-05-07 | 103,022,677 | [10-Q 2025-05-15] |
| 2025-08-07 | 107,595,421 | [10-Q/A 2025-08-15] |
| 2025-11-07 | 122,801,572 | [10-Q 2025-11-13] |
| 2026-03-26 | 158,481,243 | [10-K 2026-03-31] |
| 2026-04-28 | 8,087,955 | [10-K/A 2026-04-30] |
| 2026-05-07 | 8,330,270 | [10-Q 2026-05-14] |
| 2026-08-11 | 13,649,384 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-08-28; declared effective 2026-09-09 [S-3 2026-08-28]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-04-23. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-04-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-04-23] |
| 2026-02-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-02-09] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-28 | Forterre Gael | other | 284 | $0.25 | [4 2026-09-30] |
| 2026-09-28 | Michel Gaetan | other | 608 | $0.25 | [4 2026-09-30] |
| 2026-03-17 | Forterre Gael | other | 5,251 | $0.19 | [4 2026-03-19] |
| 2026-03-17 | Rootsaert Rodney Gerard | other | 3,948 | $0.19 | [4 2026-03-19] |
| 2026-03-17 | Micallef Jacob Vincent | other | 5,310 | $0.19 | [4 2026-03-19] |
| 2026-03-17 | Plummer Nicholas | other | 7,003 | $0.19 | [4 2026-03-19] |
| 2026-03-01 | Rootsaert Rodney Gerard | other | 3,321 | $0.21 | [4 2026-03-03] |
| 2026-03-01 | Forterre Gael | other | 2,283 | $0.21 | [4 2026-03-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-25 | 8-K | Unregistered sale of equity |
| 2026-09-16 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-15 | 8-K | Unregistered sale of equity |
| 2026-09-14 | 8-K | Other events |
| 2026-09-09 | S-3/A | Registration statement |
| 2026-09-08 | S-3/A | Registration statement |
| 2026-09-04 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-02 | 8-K | Material agreement entered |
| 2026-09-02 | 8-K | Unregistered sale of equity |
| 2026-08-28 | S-3 | Registration statement |
| 2026-08-24 | 8-K | Unregistered sale of equity |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $VNRX
Email me when Volitionrx Ltd files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.